Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells 11,750 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 11,750 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the transaction, the chief operating officer now owns 538,932 shares of the company’s stock, valued at $6,510,298.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Monday, April 8th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.74, for a total value of $173,209.74.
• On Friday, April 5th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.58, for a total transaction of $171,329.58.
• On Wednesday, March 6th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.99, for a total transaction of $164,396.49.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $11.26 on Monday. The company has a market capitalization of $2.41 billion, a price-to-earnings ratio of -102.36 and a beta of 0.97. The company’s fifty day moving average price is $14.01 and its 200-day moving average price is $10.31. Hims & Hers Health, Inc. has a one year low of $5.65 and a one year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.03. The business had revenue of $246.60 million for the quarter, compared to the consensus estimate of $245.84 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business’s revenue was up 47.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.05) earnings per share. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.11 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Graham Capital Management L.P. lifted its holdings in shares of Hims & Hers Health by 39.4% in the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock valued at $2,141,000 after acquiring an additional 96,277 shares during the last quarter. Swiss National Bank increased its position in Hims & Hers Health by 9.2% during the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after acquiring an additional 26,100 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after acquiring an additional 428,671 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Hims & Hers Health by 11.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock worth $3,551,000 after purchasing an additional 58,288 shares during the period. Finally, Must Asset Management Inc. bought a new position in Hims & Hers Health during the 3rd quarter valued at about $1,596,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the topic of several analyst reports. TheStreet raised Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Jefferies Financial Group reaffirmed a “hold” rating and set a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Truist Financial boosted their target price on Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. Imperial Capital raised Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price target on the stock in a report on Wednesday, February 28th. Finally, Canaccord Genuity Group began coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective for the company. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health presently has an average rating of “Moderate Buy” and a consensus price target of $14.85.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.